REGN

AI Research

Dupixent EU Approval in Children + Obesity Phase 3 Results → Buy Consensus at $820 Average PT

Regeneron's Dupixent was recommended for EU approval to treat chronic spontaneous urticaria in young children, expanding the drug's label and addressable market beyond its existing indications. The company is also gaining attention for strong Phase 3 trial results for its obesity treatment, positioning it as a potential challenger in the high-growth GLP-1 and obesity drug market. Regeneron's Q4 2025 results surpassed expectations with 3% revenue growth and adjusted EPS of $11.44, with 24 analysts rating it Buy and an average 12-month price target of $819.54, representing roughly 10% upside from the current price of $756.91.